Skip to main content

Table 2 Visite schedule

From: Comparative effectiveness trial of transoral head and neck surgery followed by adjuvant radio(chemo)therapy versus primary radiochemotherapy for oropharyngeal cancer (TopROC)

 

Baseline

Randomization

Treatment phase (start within 4 weeks after randomization)

Treatment Arm

  

Arm A (8–17 weeks)

Arm B (6–11 weeks)

   

Postoperative Visit

Intermediate Visiti

Final Visit

Intermediate Visiti

Final Visit

Study week (W)

−4

0

1–4

9–13

12–17

3–7

6–11

Informed consentb(Study and translational research)

-4

      

Medical history incl. smoking and alcohol, demographics

X

      

Eligibility criteriaa

X

      

CT or MRI Neck

X

      

CT Chest/Abdomen

X

      

Physical examinationb

−2

 

X

X

X

X

X

Performance status/ASA

−2

 

X

X

X

X

X

Vital signsc

−2

 

X

X

X

X

X

Laboratory determinationsd

X

 

X

X

X

X

X

Panendoscopy, FFPE tissuea

X

 

Xe

    

Audiometry

X

   

X

 

X

Blood draw translat. researcha

X

 

X

Xj

X

Xj

X

Dental evaluation and panoramic view as indicated

X

      

Postoperative morbiditya

X

 

X

X

X

  

Swallowing functiona f

X

 

X

X

X

X

X

Nutritional evaluation

X

      

Quality of life assessmenta g

X

 

X

X

X

X

X

Health Care Utilization and Productivity lossa h

X

      

Monitoring AE’s/SAE’sa

  

X (Randomization to 28 days after the last administration of IMP

and/or 5 months after randomization in this trial)

Survival

  

X

  1. aStudy specific procedures
  2. bincluding weight, height (only baseline)
  3. cblood pressure, heart rate, body temperature. ECG at baseline and as clinically indicated
  4. dhaematology panel (haemoglobin, platelets, WBC with neutrophils, lymphocytes, monocytes, eosinophils, and basophils), chemistry panel (sodium, potassium, calcium, serum creatinine, alkaline phosphatase, AST, ALT, total and direct bilirubin, CrP; glomerular filtration rate by MDRD, coagulation (INR, aPTT, PT). HIV and ß-HCG only at baseline and as clinically indicated
  5. esurgical resected tumor specimen
  6. fMDADI Score (Appendix E)
  7. gQuality of life assessments using EQ-5D-5L, EORTC QLQ-C30, QLQ H&N-43 (Appendix D)
  8. hSelf-report inventory based on FIMA (Appendix A) and sociodemographic evaluation (Appendix I)
  9. i3 weeks after start of CRTX
  10. jwithin 2 weeks after end of CRTX